Maybe we'll get some insight here...
Rigel to Present at the Adams Harkness 2004 Summer Seminar on August 4th.
2004-07-28 16:10 (New York)
SOUTH SAN FRANCSICO, Calif., July 28 /PRNewswire-FirstCall/ -- Rigel
Pharmaceuticals, Inc. (Nasdaq: RIGL) will present at the 24th Annual Adams
Harkness 2004 Summer Seminar on Wednesday, August 4, 2004 at 2:00 p.m.
(Eastern time) at the Marriott Long Wharf Hotel in Boston. James M. Gower,
Rigel's chairman and chief executive officer will discuss Rigel's clinical
trials addressing allergy and hepatitis C, as well as, describe the company's
current plans to initiate clinical development for at least one new indication
each year.
To access the live audio webcast or the subsequent archived recording, log
on to www.rigel.com/rigel/events. Please connect to Rigel's website several
minutes prior to the start of the conference call to ensure adequate time for
any software download that may be necessary.
About Rigel (www.rigel.com)
Rigel's mission is to become a source of novel, small-molecule drugs to
address large, unmet medical needs. We have initiated four development
programs: asthma/allergy, hepatitis C, rheumatoid arthritis and oncology.
Rigel has begun clinical testing of its first two product candidates, R112 for
allergic rhinitis and R803 for hepatitis C, and expects to begin clinical
trials of R406 for the treatment of rheumatoid arthritis by the end of 2004,
to be followed by clinical trials for drug candidates in oncology and asthma. |
